Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;3(5):324-329.
doi: 10.1016/j.jpha.2013.02.001. Epub 2013 Mar 14.

Determination of sodium hyaluronate in pharmaceutical formulations by HPLC-UV

Affiliations

Determination of sodium hyaluronate in pharmaceutical formulations by HPLC-UV

K Ruckmani et al. J Pharm Anal. 2013 Oct.

Abstract

A liquid chromatography (HPLC) method with UV detection was developed for determination of sodium hyaluronate in pharmaceutical formulation. Sodium hyaluronate is a polymer of disaccharides, composed of d-glucuronic acid and d-N-acetylglucosamine, linked via alternating β-1, 4 and β-1, 3 glycosidic bonds. Being a polymer compound it lacks a UV absorbing chromophore. In the absence of a UV absorbing chromophore and highly polar nature of compound, the analysis becomes a major challenge. To overcome these problems a novel method for the determination of sodium hyaluronate was developed and validated based on size exclusion liquid chromatography (SEC) with UV detection. An isocratic mobile phase consisting of buffer 0.05 M potassium dihydrogen phosphate, pH adjusted to 7.0 using potassium hydroxide (10%) was used. Chromatography was carried out at 25 °C on a BioSep SEC S2000, 300 mm×7.8 mm column. The detection was carried out using variable wavelength UV-vis detector set at 205 nm. The compounds were eluted isocratically at a steady flow rate of 1.0 mL/min. Sodium hyaluronate retention time was about 4.9 min with an asymmetry factor of 1.93. A calibration curve was obtained from 1 to 38 g/mL (r>0.9998). Within-day % RSD was 1.0 and between-day % RSD was 1.10. Specificity/selectivity experiments revealed the absence of interference from excipients, recovery from spiked samples for sodium hyaluronate was 99-102. The developed method was applied to the determination of sodium hyaluronate in pharmaceutical drug substance and product.

Keywords: Chromophore; Derivatization; Hyaluronic acid; Size exclusion chromatography; Sodium hyaluronate.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Mobile phase: 0.01 M phosphoric acid, pH adjusted to 3.0 using 10% potassium hydroxide, flow rate 0.50 mL/min, column, ultrahydrogel, 300 mm×7.8 mm, 1000 Å and detector wavelength set at 205 nm. (B) Mobile phase: 0.1 M ammonium dihyrogen phosphate, flow rate 0.50 mL/min, column, ultrahydrogel, 300 mm×7.8 mm, 1000 Å and detector wavelength set at 205 nm.
Fig. 2
Fig. 2
Effect of pH on retention time, detection response (peak area) and efficiency (as shown as plate number N/column) of sodium hyaluronate. Column, BioSep SEC S2000, 300 mm×7.8 mm, mobile phase: 0.05 M potassium hydrogen phosphate, pH adjusted to shown below using potassium hydroxide (10% solution), flow rate of l.0 mL/min, wavelength set at 205 nm and injection volume 10 μL.
Fig. 3
Fig. 3
Effect of buffer on detection response (peak area) and capacity factor of sodium hyaluronate. Column, BioSep SEC S2000, 300 mm×7.8 mm, mobile phase: buffer (potassium hydrogen phosphate) at varied concentration as shown in below, pH adjusted to 7.0 using potassium hydroxide (10% solution), flow rate of l.0 mL/min,wavelength set at 205 nm and injection volume 10 μL.
Fig. 4
Fig. 4
A typical HPLC chromatogram of sodium hyaluronate. Mobile phase: 0.05 M potassium dihydrogen phosphate, pH adjusted to 7.0 using potassium hydroxide (10% solution). Column, BioSep SEC S2000, 300 mm×7.8 mm, flow rate of l.0 mL/min, wavelength was set at 205 nm and injection volume 10 μL.
None

Similar articles

Cited by

References

    1. Poulson J.H. Urine and tissue glycosaminoglycan and their interactions. Dan. Med. Bull. 1975;33:75–96. - PubMed
    1. Frasher J.R.E., Laurent T.C., Laurent UBG. Hyaluronan: its nature, distribution, function and turnover. J. Intern. Med. 1997;242:27–33. - PubMed
    1. Sten R. Hyaluronan catabolism: a new metabolic pathway. Eur. J. Cell Biol. 2004;83(7):317–325. - PubMed
    1. Sugahara K., Schwartz N.B., Dorfma A. Biosyntheses of hyaluronic acid by streptococcus. J. Bio. Chem. 1979;254(14):6252–6261. - PubMed
    1. Wessels M.R., Moses A.E., Goldberg JB. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc. Natl. Acad. Sci. 1991;88(19):8317–8321. - PMC - PubMed